Nuvectis Pharma, Inc. · NASDAQ:NVCT
Nuvectis Pharma — Investor Presentation (March 2025)
27 slides from Nuvectis Pharma's investor presentation, March 2025
Slide 1: Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. Innovative Precision Medicine for Serious Conditions of Unmet Medical Need in Oncology March 2025 (NASDAQ: NVCT)
Slide 2: Forward Looking Statements
Forward Looking Statements Nuvectis Pharma, Inc. Certain statements in this presentation constitute “forward-looking statements“within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties. All statements, other than statements of historical
Slide 3: Nuvectis Pharma – Key Highlights
Nuvectis Pharma – Key Highlights Our Approach to Select and acquire novel, rationally-designed drug candidates Precision Medicine Focus on drug development for serious conditions of unmet need in oncology Ongoing clinical trials NXP800 • ARID1a-mutated, platinum resistant ovarian carcinoma (Fa
Slide 4: Management Team
Management Team Track record of success Ron Bentsur Enrique Poradosu, PhD Shay Shemesh Chairman & Chief Executive Officer Chief Scientific & Business Officer Chief Development & Operations Officer Jelmyto® (mitomycin) NuvectisPharma, Inc. 4
Slide 5: Nuvectis Precision Medicine Pipeline
Nuvectis Precision Medicine Pipeline NuvectisPharma, Inc. 5
Slide 6: About NXP800
About NXP800
Slide 7: NXP800 Mechanism of Action
NXP800 Mechanism of Action NXP800 is a GCN2 kinase activator Cell proliferation (% of vehicle control) 150 NXP800 CCT361814 NXP800 + A92+(GCN2 CCT361814 A92 @inhibitor) 1000nM 100 50 NXP800 activates the GCN2 kinase 0 1 10 100 1000 10000 Created with BioRender.com NXP800 (nM) [CCT361814] (nM) Inhi
Slide 8: Substantial Antitumor Activity in ARID1a-Mutated Ovarian Carcinoma Xenografts
Substantial Antitumor Activity in ARID1a-Mutated Ovarian Carcinoma Xenografts (NXP800 vs. Cisplatin) Preclinical proof of concept leading to selection of initial target indication SKOV-3 (Cisplatin Resistant) TOV-21G (Cisplatin Sensitive) Est. Total Est. # of Patients Disease Incidence w/ ARID1a (US
Slide 9: Substantial Antitumor Activity in Cholangiocarcinoma
Substantial Antitumor Activity in Cholangiocarcinoma Additional potential development opportunities Cholangiocarcinoma (CCA) is a lethal malignancy with poor prognosis arising from the biliary tree a Approx. 10,000 new cases/year in the US a. The cholangiocarcinoma foundation, cholangiocarcinoma
Slide 10: NXP800 Potential Opportunity in Multiple Cancers
NXP800 Potential Opportunity in Multiple Cancers ARID1a is an important mutation that can be used as a patient selection strategy a Estimated Incidence ARID1a mutation Estimated Number of Patients Indication (US) prevalence with ARID1a protein loss (US) Ovarian Cancer 4,350 52.9% 2,300 (Clear Cell a
Slide 11: Recent Data Update from Ongoing Phase 1b
Recent Data Update from Ongoing Phase 1b Three dosing regimens have been evaluated to date in twelve patients • QD regimen: 75 mg/day and 50 mg/day, each regimen administered to two patients • Intermittent regiment: eight patients were treated with 50 mg/day on a five days on / two days off schedu
Slide 12: About NXP900
About NXP900
Slide 13: NXP900 Key Highlights
NXP900 Key Highlights Discovered at the University of Edinburgh, Scotland Precision Medicine A potent, novel, small molecule inhibitor of YES1/SRC signaling Approach YES1-Hippo pathway alteration associated with sensitivity to NXP900 in squamous cell models Differentiated Highly selective Fe
Slide 14: NXP900 Kinome Profiling Demonstrates High Selectivity
NXP900 Kinome Profiling Demonstrates High Selectivity NXP900 Dasatinib Note: Dasatinib data from Remsing Rix et al., Leukemia 23, 477–485 (2009), NXP900 data from AACR 2022. NuvectisPharma, Inc. 14
Slide 15: NXP900 Completely Shuts Down Signaling of Non-receptor Tyrosine Kinases of the SRC Family
NXP900 Completely Shuts Down Signaling of Non-receptor Tyrosine Kinases of the SRC Family Differentiated vs. other multi-kinase inhibitors that only achieve a partial SRC pathway shut down NXP900: Complete shutdown of Other multi-kinase inhibitors: Partial No inhibitor: Fully active SRC the SRC path
Slide 16: Single Agent Strategy 1: YES1 Gene Amplification
Single Agent Strategy 1: YES1 Gene Amplification A patient with YES1-amplified lung adenocarcinoma with no established primary driver alteration responded to SFK inhibition a Case Study Hypothesis confirmation achieved in vivo with NXP900 in a 81 y/o man diagnosed with de novo stage 4 lung adenoca
Slide 17: Single Agent Strategy 2: Targeting YES1 in Cancers of Squamous Cell Origin
Single Agent Strategy 2: Targeting YES1 in Cancers of Squamous Cell Origin Mechanistic Rationale Biomarker Activity Preclinical POC In Vivo KYSE-140 - Esophageal Cancer CAL27 - Head and Neck Cancer (tongue) Created with BioRender.com Hippo pathway alterations (FAT1-4, YAP1, TAZ) are highly prevale
Slide 18: NXP900 Single Agent: Market Opportunity
NXP900 Single Agent: Market Opportunity NuvectisPharma, Inc. 18
Slide 19: Combination Strategy
Combination Strategy YES1 and SRC have been validated in development of resistance to EGFR and ALK inhibitors in NSCLC ALK and EGFR targeted agents have demonstrated potent and durable activity in NSCLC. However, emergence of resistance to ALK and EGFR targeting drugs is inevitable. SRC, YES1
Slide 20: NXP900/osimertinib Synergy in vitro and in vivo in Osimertinib-resistant NSCLC Cells
NXP900/osimertinib Synergy in vitro and in vivo in Osimertinib-resistant NSCLC Cells NXP900 restores sensitivity in vitro to osimertinib in resistant cells at low nanomolar concentrations Combination achieves potent tumor regression in vivo and longer duration of the response after end of treatment
Slide 21: Resistance to ALK Inhibitors in NSCLC
Resistance to ALK Inhibitors in NSCLC Acquired resistance to ALK inhibitors increases single agent sensitivity to NXP900 in vitro NXP900 inhibits proliferation of crizotinib resistant cells NXP900 demonstrated potent single agent activity Cell line Alectinib Lorlatinib NXP900 in ALK fusion driven
Slide 22: NXP900/lorlatinib Synergy in vitro in ALK-driven NSCLC Cells
NXP900/lorlatinib Synergy in vitro in ALK-driven NSCLC Cells Overlays Isobologram #Ok #Ok NXP900 + lorlatinib in NCI-H2228 cells 50% inh. Isobologram NXP900 + lorlatinib in NCI-H2228 NXP900 lorlatinib NXP900 + lorlatinib 1 : 1 4.2 NXP900 + lorlatinib 4 : 1 Singles NXP900 + lorlatinib 1 : 4 NXP900 +
Slide 23: NXP900 Combination in NSCLC: Market Opportunity
NXP900 Combination in NSCLC: Market Opportunity Adapted from: Targeted therapy for rare lung cancers: Status, challenges, and prospects (Mol Therapy, 2023) Despite the demonstrated clinical activity of ALK and EGFR targeting agents in NSCLC, development of resistance to treatment is inevitable P
Slide 24: NXP900: Phase 1a Ongoing
NXP900: Phase 1a Ongoing Patients with advanced solid tumors Clinicaltrials.gov NCT05873686 Phase 1a Dose Escalation Starting dose of 20 mg, QD Primary Objective: Select doses/schedules for Phase 1b Key Endpoints: Assess Pharmacokinetics, pharmacodynamics, lab abnormalities, dose limiting toxicities
Slide 25: Financial and NVCT Stock Highlights
Financial and NVCT Stock Highlights Financials Insider Ownership Ticker NVCT Founders and >5% holders Approx. 60% $18.5 million as of December 31, Cash 2024; raised $15.5M in February ‘25 Research Coverage Roth-MKM Jonathan Aschoff Ladenburg Thalman Aydin Huseynov Lucid Capital Markets Christopher L
Slide 26: Nuvectis Investment Highlights
Nuvectis Investment Highlights Precision medicine pipeline for serious conditions of unmet medical need in oncology Follow up data and completion of the Phase 1b study of NXP800 in platinum resistant, ARID1a- 2025 Milestones mutated ovarian cancer; completion of the Phase 1a dose escalation study
Slide 27: Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. Innovative Precision Medicine for Serious Conditions of Unmet Medical Need in Oncology March 2025 (NASDAQ: NVCT)